When administered to patients with NASH for 12 weeks, aldafermin (up to 6 mg daily) reduced liver fat content by up to 60% relative to baseline, reduced ALT by about 50%, and decreased Pro-C3 by about 20–25% (31). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.